This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Valeant Pharmaceuticals International Inc (VRX)

NYSE: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 600.34M 916.09M 164.11M 394.27M
Receivables 1.81B 913.84M 577.50M 283.06M
Inventories 882.97M 531.26M 355.21M 229.58M
Other Current Assets 15.94M 90.98M 72.24M 4.01M
Total Current Assets 3.89B 2.78B 1.36B 1.02B
Property, Plant & Equipment, Gross 2.07B 636.23M 540.03M 404.46M
Accumulated Depreciation & Depletion 838.84M 173.51M 125.79M 122.71M
Property, Plant & Equipment, Net 1.23B 462.72M 414.24M 281.75M
Intangibles 12.85B 9.31B 7.66B 6.37B
Other Non-Current Assets 195.47M 183.75M 58.70M 38.96M
Total Non-Current Assets 24.08B 15.17B 11.78B 9.77B
Liabilities & Shareholder Equity
Total Assets 27.97B 17.95B 13.14B 10.80B
Accounts Payable 326.97M 227.38M 157.62M 101.32M
Short Term Debt 204.76M 480.18M 111.25M 116.90M
Other Current Liabilities 114.46M 19.91M 110.60M 9.80M
Total Current Liabilities 2.51B 1.82B 924.27M 692.46M
Long Term Debt 17.16B 10.54B 6.54B 3.57B
Deferred Income Taxes 2.32B 1.35B 1.24B 1.44B
Other Non-Current Liabilities 742.93M 522.82M 434.65M 180.34M
Minority Interest 2.47M 0.00 0.00 0.00
Total Non-Current Liabilities 20.34B 12.41B 8.21B 5.19B
Total Liabilities 22.85B 14.23B 9.13B 5.88B
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 5.12B 3.72B 4.01B 4.91B
Common Par 0.00 0.00 0.00 0.00
Additional Paid In Capital 8.53B 6.21B 6.24B 5.75B
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -3.28B -2.37B -2.03B -934.51M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments -132.78M -119.40M -202.43M 98.84M
Total Capitalization 22.28B 14.25B 10.55B 8.49B
Total Equity 5.12B 3.72B 4.01B 4.91B
Total Liabilities & Stock Equity 27.97B 17.95B 13.14B 10.80B
Total Common Shares Outstanding 333.04M 303.86M 306.37M 302.45M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 321.00M 305.45M 304.66M 195.81M
Diluted Weighted Shares Outstanding 321.00M 305.45M 326.12M 195.81M
Number of Employees 17200 7000 6900 4300
Number of Part-Time Employees 0 0 0 0
VRX News

VRX Valeant Pharmaceuticals International Inc

Analysts Ratings for VRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 8 8 8
Moderate Buy 1 1 1 1
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET VRX ANALYST REPORT

Brokerage Partners

VRX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs